Emergency Hemostasis No Longer Relies on Zeolite: Nanjing Nanyuan Bio Raises Tens of Millions in Pre-A Round

VCBeat recently learned of the Functional Polysaccharide Development and Production Innovation Platform:Nanjing Nanfangyuan Biotechnology Co., Ltd.(hereinafter referred to as "Nanfang Yuan") secured tens of millions of RMB in its Pre-A round of financing, which was led bySuzhou Yanying Investment Management Co., Ltd. Led the Investment，Changzhou Zhengkaifeng Venture Capital Partnership (Limited Partnership)Co-investment.The funds raised in this round are planned to be used for raw material preparation, quality system development, and preclinical product research.

Nanfang Yuan was established in January 2022., and secured approximately RMB 10 million in angel financing during the same period.Its founding teamAtFunctional Polysaccharide FieldandMetabolic Drug SectorwithOver 30 years of experience in academic research, drug development, and industrialization, with over 100 Category I scientific papers published. The team has built an industry-leadingInnovative Functional Polysaccharide Synthetic Biology Technology Platform, and jointly established with Nanjing University of Science and TechnologyKey Laboratory of Metabolic Engineering and Biosynthesis Technology, Ministry of Industry and Information Technology, and has successfully commercialized multiple products.

Nanfang Yuan currently leverages this technology platform primarily to apply functional polysaccharides in two areas: novel hemostatic materials and long-acting medical aesthetic fillers, registering its products as Class III medical devices.

A large number of preclinical studies have confirmed Nanfang Yuan’s patentInnovative Hemostatic Polysaccharide Hemoadhicanthrough its unique hemostatic properties, superior biocompatibility, and safety,Replacing the Hemostatic Function of Traditional Zeolites, and achieve trueInstant Hemostasis, capable ofFully meets the hemostatic needs in emergency scenarios for military, police, traffic, industrial and mining, and household applications., while also enabling product forms such as absorbable hemostatic powder, hemostatic gel, hemostatic gauze, and hemostatic sponge to meet clinical medical needs. The entire product series holds global patents, with registration proceedings progressing smoothly in China, the United States, and Europe. The products are expected to be launched sequentially starting in 2024.

ForMedical Aesthetics Market, Nanfang Yuan developedNew Series of Medical Aesthetic Raw Materials: Silk Sugar Lubcan, itsPossesses all the fundamental advantages of hyaluronic acid, while achieving improvements in longevity, integration, and cost-effectiveness.. Currently, Nanfang Yuan is making every effort to buildLong-Lasting Medical Aesthetic Fillers。

Functional polysaccharides represent a market with a long development history and a rich pipeline of investigational products, but the series of products currently launched by Nanfang Yuan are allPrecisely addresses existing clinical needs and product pain pointsRegarding emergency hemostatic materials for trauma, currently only two non-Chinese products have received FDA approval for market entry worldwide, while China still prioritizes zeolite powder, which has significant side effects, as the preferred product in this application scenario. Nanfang Yuan is currently accelerating preclinical trials for this category of products and actively promoting the commercialization of this globally leading product.

In the future, Nanfang Yuan will leverage its innovation platform for the development and production of functional polysaccharides to continue expanding the applications of functional polysaccharides in the vast dual-use (civilian and military) market.Hemostatic gels for treating rebleeding in neurosurgery, hemostatic sponges for post-extraction bleeding, anorectal hemostatic materials, bone repair materials, and non-injectable aesthetic materials will all fall within the scope of Nanfang Yuan’s future product development.。

Based on a thorough understanding of its own sustainable innovation capabilities and precise judgment of this vast market, Nanfang Yuan will fully open itself to global market competition during the upcoming critical development phase.From quality system standards and project design layout to product registration and filing, Nanfang Yuandu is committed to achieving a globally leading level.

“Technology can do more than calculate ballistic trajectories; it can also repair bodies damaged by them. Saving lives and healing the wounded, thereby alleviating the tragedy of lives lost in accidents, is the responsibility and aspiration of Nanfang Yuan.”Professor Zhang Jianfa, Founder and Chairman of Nanfang YuanEarnestly arriving.

Suzhou Yanying Investment Management Co., Ltd. is the investment platform under Suzhou Xiangtang Group, responsible for managing and operating the group’s investment sector. It has led the investment, management, and exit strategies for projects including Joinn Laboratories, Staidson Biopharma, Dewei New Materials, Nanwei Shares, and Conatus Pharmaceuticals. The company established and operates the Yanying No. 1 and Yanying No. 2 funds, with a total fundraising scale of RMB 300 million. Its investment portfolio primarily includes star enterprises that are either already listed or preparing for IPOs, such as Zai Lab, Jiangsu Boyun, Shanghai Zhuoran, Suzhou Xiangyuan, Biocytogen, Zhizhu Technology, Taili Biology, Huihe Medical, Ruipai Medical, and Luosheng Biology. The firm focuses on innovative new drugs while also covering pre-IPO projects in other high-tech fields.